Prospective Study of Tissue-Resident Immune Cells and Acute Graft-versus-Host Disease After Stem Cell Transplant

What this Trial Is About

Researchers are investigating how different tissue-resident immune cell types relate to the development and progression of acute graft-versus-host disease aGVHD following hematopoietic stem cell transplantation. This prospective, observational study aims to understand these immune cells role by following patients with varying severity of aGVHD. Approximately 40 participants will be enrolled, including 20 patients with severe grade 3-4 aGVHD and 20 with milder grade 1-2 aGVHD. The study does not provide any treatments or randomize participants instead, patients will continue to receive usual care as determined by their doctors. Participants will be followed monthly over about three months, from November 2024 to February 2025. During this time, researchers will observe and collect data related to immune cell subsets in organs and their association with aGVHD severity and patient outcomes. Participants will be monitored regularly to assess acute graft-versus-host disease status, overall survival, and disease-free survival during the 100-day follow-up. Data collection will include grading aGVHD according to established guidelines. The study focuses on understanding immune cell behavior without altering treatment, allowing researchers to observe natural disease progression and outcomes in real-world care settings.

Tissue-resident Immune Cell Subsets in aGVHD